1497 / 1631
Role of radiation therapy in primary breast DLBCL in the
Rituximab era: a SEER database analysis
Liu, Cancer Medicine 2018
Aim:
•
Evaluate role of consolidation RT in PB-DLBCL patients treated
with rituximab
Patients:
•
PB-DLBCL diagnosed 2001- 2014
•
N=386
•
52% received RT
•
Median age: 64 years (range, 19–93 years)
•
Median fup time: 45 months (range, 0–167 months)